Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT01975818

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01975818
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01975818. Randomized; no masking; primary purpose treatment. Start 2013-10-28 (actual); primary completion 2015-10-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
Acronym
DIALOGUE4
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Molidustat (BAY 85-3934)
Intervention (Biological)
Epoetin alfa/beta
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01975818
Content hash
1e5a2f77e0a593f5f060e6937f35e36e887cc5f4d7cb3c13ad3b447c7d7c7355